Transcode Therapeutics Inc (RNAZ)

Finanzdaten der Transcode Therapeutics Inc-Aktie (RNAZ)

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Periodenlänge	3 Monate	3 Monate	3 Monate	3 Monate	3 Monate
	61.76%6.79	17.76	16.03	4.56	4.22
Research and Development	27.67%3.69	5.11	5.48	3.16	2.57
Operating Income/Loss	61.76%-6.79	-17.76	-16.03	-4.56	-4.22
Nonoperating Income/Loss	80.29%0.04	0.20	2.81	-0.29	-0.06
Income/Loss From Continuing Operations Before Tax	61.55%-6.75	-17.55	-	-4.86	-4.28
Income Tax Expense/Benefit, Deferred	99.87%0.00	0.23	-	-	-
	62.05%-6.75	-17.79	-13.44	-4.86	-4.28
Attributable To Parent	62.05%-6.75	-17.79	-13.44	-4.86	-4.28
Available To Common Stockholders, Basic	64.81%-6.87	-19.51	-15.05	-4.86	-4.28
Basic Average Shares	4.39%0.96	0.92	-	0.83	0.83
Diluted Average Shares	4.39%0.96	0.92	-	0.83	0.83
Basic Earnings Per Share	66.31%-7.17	-21.28	-	-5.82	-5.13
Diluted Earnings Per Share	66.31%-7.17	-21.28	-	-5.82	-5.13